Home | Welcome to Contract Pharma   
Last Updated Thursday, August 21 2014
Print

Financial Report: Biogen Idec



Published April 23, 2014
Biogen Idec
 
1Q Revenues:
$2.1 billion (+51%)

1Q Earnings: $480 million (+12%)

Comments: TECFIDERA, recently approved for MS patients in Europe, had revenues of $506 million, comprised of $460 million the U.S. and approximately $46 million outside the U.S. AVONEX revenues increased 2% to $761 million. TYSABRI revenues were up 41% to $441 million due to recording 100% its revenues following the acquisition of complete asset rights in 2Q13. RITUXAN and GAZYVA revenues from an unconsolidated joint business arrangement were $297 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On